Roivant Sciences Ltd
F:87S
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
7.95
11.885
|
| Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Roivant Sciences Ltd
Roivant Sciences Ltd
Interest Income Expense
Roivant Sciences Ltd
Interest Income Expense Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Interest Income Expense | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Roivant Sciences Ltd
F:87S
|
Interest Income Expense
$63.7m
|
CAGR 3-Years
-11%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
|
Interest Income Expense
$570k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Autolus Therapeutics PLC
NASDAQ:AUTL
|
Interest Income Expense
-$29m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bicycle Therapeutics PLC
NASDAQ:BCYC
|
Interest Income Expense
$27.8m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
110%
|
CAGR 10-Years
N/A
|
|
|
Immunocore Holdings PLC
NASDAQ:IMCR
|
Interest Income Expense
-£344k
|
CAGR 3-Years
21%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Genus PLC
LSE:GNS
|
Interest Income Expense
-£200k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
24%
|
|
Roivant Sciences Ltd
Glance View
Roivant Sciences Ltd. is a dynamic biopharmaceutical company that has carved a unique niche in the pharmaceutical landscape by focusing on the efficient development of innovative therapies. Founded in 2014, Roivant operates on a model that leverages technology and data to accelerate drug discovery and commercialization, which allows it to bring treatments to market more swiftly than traditional pharmaceutical firms. With a roster of subsidiary companies, each specializing in different therapeutic areas, Roivant aims to tackle unmet medical needs, particularly in neuroscience, immunology, and rare diseases. This approach not only diversifies its portfolio but also enhances the potential for successful product launches, appealing to investors looking for promising biotech opportunities. At the heart of Roivant's strategy is its commitment to harnessing innovative technologies, including artificial intelligence and decentralized clinical trials, that streamline the drug development process. The company has established partnerships with leading research institutions and pharmaceutical giants, enhancing its credibility and expanding its reach. As Roivant progresses through clinical trials and advances its pipeline, investors are provided with unique opportunities to participate in groundbreaking treatments that could improve patient outcomes and generate significant returns. With its nimble structure, emphasis on collaboration, and pursuit of disruptive innovations, Roivant stands out as a compelling player in the evolving world of biopharmaceuticals, representing both promise and potential for those willing to engage with its journey.
See Also
What is Roivant Sciences Ltd's Interest Income Expense?
Interest Income Expense
63.7m
USD
Based on the financial report for Mar 31, 2024, Roivant Sciences Ltd's Interest Income Expense amounts to 63.7m USD.
What is Roivant Sciences Ltd's Interest Income Expense growth rate?
Interest Income Expense CAGR 3Y
-11%
The average annual Interest Income Expense growth rates for Roivant Sciences Ltd have been -11% over the past three years .
You don't have any saved screeners yet
